Trial results for a Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study were posted on ClinicalTrials.gov on 2026-05-05, indicating preliminary efficacy in reducing decisional conflict with a p-value of 0.01 in one analysis and 0.03 in another.
Background
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder often managed with medication. Decisions regarding medication use can be complex, particularly for adolescents and their families, leading to uncertainty. There is a recognized need to involve adolescents more actively in their treatment decisions. This pilot study aimed to explore whether a personalized medication experiment intervention could increase adolescent involvement in decision-making and decrease uncertainty about future medication use.
Trial design
This completed study, identified as Phase NA, enrolled 31 participants with Attention Deficit Hyperactivity Disorder. The trial was an open-label pilot designed to test the feasibility, acceptability, and preliminary efficacy of a personalized medication experiment intervention. The central hypothesis was that the intervention would lead to within-subject increases in adolescent involvement in decision-making and decreases in uncertainty about future medication use.
Key results
The study collected data on several measures, including the Decision Making Involvement Scale and Decisional Conflict. For Decisional Conflict, parent-reported mean scores changed from 15.9 (Standard Deviation: 13.7) to 9.3 (Standard Deviation: 10.0). Child-reported mean scores for Decisional Conflict changed from 26.3 (Standard Deviation: 11.6) to 22.5 (Standard Deviation: 13.1). On the Decision Making Involvement Scale [Parent Seek], child-reported mean scores changed from 2.6 (Standard Deviation: 0.8) to 2.9 (Standard Deviation: 0.7). For the Decision Making Involvement Scale [Child Express], child-reported mean scores changed from 2.4 (Standard Deviation: 0.7) to 2.5 (Standard Deviation: 0.7). Statistical analyses, using a 1-sided t-test, yielded p-values of 0.03 and 0.01 for some outcomes, suggesting preliminary efficacy in line with the study's hypothesis.
What this means
The posted results suggest that personalized medication experiments may offer a promising approach to enhance adolescent involvement in ADHD treatment decisions and reduce decisional conflict. The observed changes in mean scores for decisional conflict, coupled with statistically significant p-values of 0.03 and 0.01 in certain analyses, indicate preliminary efficacy. These findings support the study's central hypothesis and suggest that this intervention warrants further investigation in larger trials to confirm its benefits for patients with ADHD and their families.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06305078, titled "Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study", were posted on 2026-05-05 on clinicaltrials.gov.